Table 1.
Composition of the study groups.
| Groups | Number of Individuals | Median Age in Years | Age Span in Years | Gender (Female/Male) |
Time Span from RT-PCR or the First/Second Vaccination to Serum Sampling in Days |
|---|---|---|---|---|---|
| SARS-CoV-2 VOC infection | 11 | 52 | 18 to 69 | 6/5 | 28 to 41 |
| SARS-CoV-2 vaccination | 100 | 41 | 18 to 62 | 77/23 | −13 to 65/15 to 49 |
| mRNA vaccines | |||||
| Pfizer/BioNTech (BNT162b2) | 33 | 45 | 23 to 62 | 25/8 | 0 to 37/15 to 49 |
| Moderna (mRNA-1273) | 11 | 48 | 33 to 61 | 7/4 | 22 to 34/20 to 22 |
| vector vaccine | |||||
| AstraZeneca (ChAdOx1 nCoV-19/AZD1222) |
56 | 31 | 18 to 60 | 45/11 | −13 to 65/ no data available yet |
mRNA: messenger ribonucleic acid; RT-PCR: one-step reverse transcription real-time polymerase chain reaction for detection of SARS-CoV-2; VOC: variant of concern.